We are live on ! Find out more
CIC

Cornercap Investment Counsel Portfolio holdings

AUM $203M
1-Year Est. Return 17.67%
This Fund
S&P 500
This Quarter Est. Return
-12.95%
1 Year Est. Return
+17.67%
3 Year Est. Return
+55.44%
5 Year Est. Return
+79.88%
10 Year Est. Return
+193.02%
AUM
$576M
AUM Growth
-$318M
Cap. Flow
-$237M
Cap. Flow %
-41.05%
Top 10 Hldgs %
8.59%
Holding
715
New
166
Increased
176
Reduced
142
Closed
157

Sector Composition

Rank Sector Weight
1 Financials 19.33%
2 Technology 14.61%
3 Healthcare 13.93%
4 Industrials 12.75%
5 Energy 8.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RNAM
501
DELISTED
Avidity Biosciences
RNAM
$156K 0.03%
+10,703
New +$159K
CCCC icon
502
C4 Therapeutics
CCCC
$412M
$154K 0.03%
+20,398
New +$179K
RYTM icon
503
Rhythm Pharmaceuticals
RYTM
$7.96B
$152K 0.03%
+36,663
New +$201K
FDMT icon
504
4D Molecular Therapeutics
FDMT
$562M
$150K 0.03%
+21,543
New +$209K
IBRX icon
505
ImmunityBio
IBRX
$8.1B
$150K 0.03%
+40,417
New +$162K
TSHA icon
506
Taysha Gene Therapies
TSHA
$1.89B
$148K 0.03%
+39,756
New +$158K
NGM
507
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$147K 0.03%
+11,499
New +$159K
CTMX icon
508
CytomX Therapeutics
CTMX
$754M
$144K 0.03%
+78,452
New +$150K
SGMO
509
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$143K 0.02%
+34,661
New +$150K
ALEC icon
510
Alector
ALEC
$199M
$141K 0.02%
+13,913
New +$139K
GRTS
511
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$140K 0.02%
+57,687
New +$152K
STRO icon
512
Sutro Biopharma
STRO
$421M
$139K 0.02%
+2,661
New +$149K
EDIT icon
513
Editas Medicine
EDIT
$442M
$138K 0.02%
+11,665
New +$156K
TCRR
514
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$138K 0.02%
+47,452
New +$117K
ORIC icon
515
Oric Pharmaceuticals
ORIC
$1.4B
$137K 0.02%
+30,508
New +$122K
BCAB icon
516
BioAtla
BCAB
$5.74M
$135K 0.02%
+948
New +$151K
KLRS
517
Kalaris Therapeutics
KLRS
$96.8M
$131K 0.02%
+1,460
New +$153K
IOVA icon
518
Iovance Biotherapeutics
IOVA
$2.87B
$128K 0.02%
+11,613
New +$152K
FULC icon
519
Fulcrum Therapeutics
FULC
$297M
$127K 0.02%
+25,941
New +$254K
JNCE
520
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$127K 0.02%
+42,065
New +$205K
SURF
521
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$124K 0.02%
+75,778
New +$157K
SRRK icon
522
Scholar Rock
SRRK
$6.44B
$123K 0.02%
+22,422
New +$161K
VKTX icon
523
Viking Therapeutics
VKTX
$4B
$121K 0.02%
+41,820
New +$103K
DTIL icon
524
Precision BioSciences
DTIL
$207M
$117K 0.02%
+2,430
New +$143K
ALLK
525
DELISTED
Allakos
ALLK
$114K 0.02%
+36,385
New +$136K

Similar funds

Cornercap Investment Counsel's Q2 2022 Portfolio in Review

As of Q2 2022, Cornercap Investment Counsel held 715 positions worth $576M, down 36% from $895M the previous quarter. Its ten largest holdings account for 8.6% of the portfolio.

Cornercap Investment Counsel withdrew a net $237M in Q2 2022, closing 157 positions and reducing 142 holdings. Its most notable exit was CornerCap Fundametrics Large-Cap ETF, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 14% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Cornercap Investment Counsel opened a new position in CBRE Group worth $1.99M.

  • Cornercap Investment Counsel's largest Q2 2022 buy was CBRE Group: 27,056 shares worth $1.99M.
  • Cornercap Investment Counsel added most to Comcast in Q2 2022, an estimated $1.9M increase.
  • Cornercap Investment Counsel's biggest Q2 2022 reduction was Eastman Chemical, cutting an estimated $3.82M.
  • Cornercap Investment Counsel fully exited CornerCap Fundametrics Large-Cap ETF in Q2 2022, selling an estimated $117M.
  • Cornercap Investment Counsel's ten largest holdings make up 8.6% of its $576M portfolio in Q2 2022.
  • Cornercap Investment Counsel opened 166 new positions and closed 157 in Q2 2022.
  • Cornercap Investment Counsel's portfolio value fell 36% quarter-over-quarter to $576M.

Based on Cornercap Investment Counsel's 13F filing for Q2 2022, filed 15 Aug 2022.